{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-090744","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.204786+00:00","generated_at":"2026-05-31T12:58:35.723975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range","bullets":["Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.","Net loss improved to $(6.1)M ($(0.16)/share) from $(13.8)M ($(0.40)/share) in Q2 2023; adjusted net income $0.0M.","Installed LDD base reached 810 units (+55% YoY); 78 LDDs sold in Q2 (+16% YoY).","FY2024 revenue guidance raised to $139-140M (56-57% growth) from prior $132-137M; gross margin guidance unchanged 68-70%.","Cash $233.3M at June 30, 2024, includes $107.5M net proceeds from public offering closed May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-090744","json":"https://secwatch.observer/filing/0000950170-24-090744.json","markdown":"https://secwatch.observer/filing/0000950170-24-090744.md","text":"https://secwatch.observer/filing/0000950170-24-090744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024090744/0000950170-24-090744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024090744/rxst-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:58:35.723975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}